Gonorrhea Market

Market Overview:

The gonorrhea market reached a value of USD 1.13 Billion across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 1.46 Billion by 2035, exhibiting a growth rate (CAGR) of 2.39% during 2025-2035.

The gonorrhea market has been comprehensively analyzed in IMARC's new report titled "Gonorrhea Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035". Gonorrhea refers to a sexually transmitted infection (STI) caused by the bacterium Neisseria gonorrhoeae. The symptoms of the ailment can vary among patients, and a few may experience no indications at all. However, when symptoms do occur, they typically manifest within 2 to 14 days after exposure. Some of the common indications in men include a burning sensation during urination, discharge from the penis (which may be white, yellow, or greenish in color), swelling or tenderness of the testicles, etc. In women, various symptoms, such as increased vaginal discharge, pain or burning during urination, pelvic pain, spotting between periods, etc., can occur. Diagnosing gonorrhea usually involves the use of laboratory tests to detect the presence of the Neisseria gonorrhoeae bacteria. The standard method of diagnosis is by sampling the potentially infected area, which can be done by using a urine sample or a swab from the urethra in men or the cervix in women. For those who engage in oral or anal sex, swabs may be taken from the throat or rectum. These samples are then analyzed by performing various testing techniques. Additionally, a culture may be taken to help determine antibiotic susceptibility.

The increasing cases of bacterial infections transmitted through sexual contact, including vaginal, anal, and oral sex, are primarily driving the gonorrhea market. In addition to this, the rising prevalence of several associated risk factors, such as lack of awareness about safe sexual practices, multiple sexual partners, history of sexually transmitted infections (STIs), etc., is acting as another significant growth-inducing factor. Moreover, the inflating demand for molecular diagnostic techniques, including nucleic acid amplification tests (NAATs), which provide highly sensitive and specific results, is further creating a positive outlook for the market. Additionally, numerous key players are making extensive investments in R&D activities to analyze the bacterium's resistance mechanisms and introduce novel antimicrobial agents that can effectively target as well as treat the infection. This, in turn, is also bolstering the market growth. Furthermore, the emerging popularity of combination therapies involving multiple antibiotics on account of their various associated benefits, such as enhanced treatment efficacy, reduced likelihood of resistance development, and improved patient outcomes, is expected to drive the gonorrhea market in the coming years. 

IMARC Group's new report provides an exhaustive analysis of the gonorrhea market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for gonorrhea and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the gonorrhea market in any manner.

Recent Developments:

• In September 2024, Innoviva Specialty Therapeutics announced that new findings on its investigational drug Zoliflodacin, a first-in-class oral, single-dose antibiotic for treating uncomplicated gonorrhea, will be presented as oral sessions at the 2024 Sexually Transmitted Infections Prevention Conference, taking place from September 16-19, 2024, in Atlanta, GA.
• In April 2024, GSK plc reported positive findings from the crucial Gepotidacin’s EAGLE-1 Phase III trial, a promising first-in-class oral antibiotic with an unprecedented mechanism of action for treating rudimentary urogenital gonorrhea (GC) in adults as well as adolescents. These results are set to be showcased on April 30, 2024, at the ESCMID Global Conference in Barcelona, Spain.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the gonorrhea market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the gonorrhea market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current gonorrhea marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the gonorrhea market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the gonorrhea market across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the gonorrhea market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of incident cases (2019-2035) of gonorrhea across the seven major markets?
• What is the number of incident cases (2019-2035) of gonorrhea by age across the seven major markets?
• What is the number of incident cases (2019-2035) of gonorrhea by gender across the seven major markets?
• What is the number of incident cases (2019-2035) of gonorrhea by type across the seven major markets?
• How many patients are diagnosed (2019-2035) with gonorrhea across the seven major markets?
• What is the size of the gonorrhea patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2025-2035) across the seven major markets?
• What are the key factors driving the epidemiological trend of gonorrhea?
• What will be the growth rate of patients across the seven major markets?
   

Gonorrhea: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for gonorrhea drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the gonorrhea market?
• What are the key regulatory events related to the gonorrhea market?
• What is the structure of clinical trial landscape by status related to the gonorrhea market?
• What is the structure of clinical trial landscape by phase related to the gonorrhea market?
• What is the structure of clinical trial landscape by route of administration related to the gonorrhea market?